Open AccessImproved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma
Author(s) -
Martin Sprinzl,
Martha M. Kirstein,
Sandra Koch,
Marie-Luise Seib,
Julia WeinmannMenke,
Hauke Lang,
Christoph Düber,
Gerrit Toenges,
Daniela Zöller,
Jens U. Marquardt,
MarcusAlexander Wörns,
Peter R. Galle,
Arndt Vogel,
Matthias Pinter,
Arndt Weinmann
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000492628
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , gastroenterology , proportional hazards model , liver cancer , oncology , neutrophil to lymphocyte ratio , lymphocyte
Inflammation affects progression of hepatocellular carcinoma (HCC). We therefore postulate that systemic inflammatory markers could help to predict prognosis in HCC patients receiving sorafenib therapy.